PMID: 11319326Apr 25, 2001Paper

Recurrent, progressive giant cell hepatitis in two consecutive liver allografts in a middle-aged woman

Journal of Clinical Gastroenterology
S NairP J Thuluvath

Abstract

In this report, we present a 41-year-old woman who developed rapidly progressive "giant cell hepatitis" that lead to end-stage liver disease. She underwent a successful liver transplantation in 1989. However, the giant cell hepatitis recurred in the allograft, resulting in cirrhosis within 4 years. She underwent a second liver transplantation in 1993. After 2 years of a relatively stable course, she again developed cirrhosis and was awaiting liver transplantation at the time of this report. The histopathologic features in the two allografts were identical to her original disease. Despite extensive investigations, no etiology for her liver disease could be found.

References

Aug 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K DevaneyK G Ishak
Oct 1, 1994·Gastroenterology·M Rabinovitz, A J Demetris
Aug 1, 1994·The American Journal of Surgical Pathology·O PappoA J Demetris

❮ Previous
Next ❯

Citations

Apr 5, 2013·Hepatitis Research and Treatment·Chhagan BihariShiv Kumar Sarin
Jul 4, 2007·Clinics in Liver Disease·Ye Htun Oo, James Neuberger
Feb 26, 2011·The Journal of Pediatrics·Giuseppe MaggioreOlivier Bernard
Sep 9, 2005·European Journal of Gastroenterology & Hepatology·Thomas KuntzenUlrich Spengler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.